US FDA approves Pfizer, Arvinas' breast cancer drug

By Padmanabhan Ananthan May 1 (Reuters) - The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' breast cancer drug for patients with an advanced form of the disease whose tumors ...

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently ​approved breast cancer drug, marking Rigel's fourth ‌commercial product on the market.

Prediction: Pfizer Will Beat the Market Over the Next 5 Years

Pfizer's financial results have been subpar in recent years. The company's newer products are starting to come into their own. The drugmaker's pipeline could lead to even more important brand-new ...

Pfizer, Arvinas ink licensing deal with Rigel for breast cancer therapy

Arvinas (ARVN) announced on Tuesday that the company and its partner, Pfizer (PFE), reached an agreement with Rigel ...

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, ...

Pfizer Posts Better-Than-Expected Revenue, Profit

Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.

Arvinas, Pfizer Tap Rigel Pharmaceuticals to Bring Veppanu to Market

Arvinas and Pfizer have chosen Rigel Pharmaceuticals to bring their recently approved breast-cancer drug Veppanu to market.